| Gaylis, Norman B |
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout |
|
|
| Recruiting | 4 | 240 | US | Pegloticase, Methotrexate | Amgen | Gout | 09/25 | 05/26 | | |
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 4 | 350 | Europe, Japan, US, RoW | Belimumab (GSK1550188), BEL (BENLYSTA) | GlaxoSmithKline | Systemic Lupus Erythematosus | 04/27 | 05/29 | | |
NCT04636229: Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 474 | US | Amniotic Suspension Allograft, Placebo | Organogenesis, Premier Research Group plc | Knee Osteoarthritis | 07/23 | 03/24 | | |
| Active, not recruiting | 3 | 243 | US | Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation | SetPoint Medical Corporation | Rheumatoid Arthritis | 05/24 | 10/27 | | |
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 03/25 | 09/25 | | |
|
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |
NCT03631225: The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 1500 | US | Vectra | Sequenom, Inc., Laboratory Corporation of America | Rheumatoid Arthritis (RA) | 09/25 | 09/25 | | |
| Mabaquiao, Arthur |
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout |
|
|
| Recruiting | 4 | 240 | US | Pegloticase, Methotrexate | Amgen | Gout | 09/25 | 05/26 | | |
| Recruiting | 4 | 1300 | US | Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab | Eli Lilly and Company, Incyte Corporation | Rheumatoid Arthritis | 12/24 | 02/26 | | |
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 34 | Europe, Canada, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 10/24 | 12/24 | | |
| Recruiting | 2/3 | 300 | Europe, US, RoW | Dapansutrile, OLT1177, Placebo Tablet | Olatec Therapeutics LLC, Olatec Therapeutics LLC | Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain | 09/25 | 10/25 | | |
NCT04368806: A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis |
|
|
| Recruiting | 2b | 140 | US | JointStem, Placebo Control | Nature Cell Co. Ltd. | Osteoarthritis, Knee | 06/24 | 12/24 | | |
| Active, not recruiting | 2 | 115 | Europe, US, RoW | DFV890, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Symptomatic Knee Osteoarthritis | 12/24 | 12/24 | | |
